Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines through an extensive global network that spans more than 110 different countries. Celltrion Healthcare provides REMSIMA, the world's first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of autoimmune disease, and innovative biopharmaceutical medications to help increase patient access to advanced therapies around the world.

For additional information on our guidelines, please visit:  
https://bit.ly/3QyOyt7

Biotechnology

Health Care

Life Sciences

Celltrion Healthcare Co.,Ltd.

Hyoung Ki Kim

Jaesung Lee

Canan Kilic

Scottie Jonghoon Kim

Paul Walden

Changwan Park

Matthew Sarabura

Kim Sung Min

Andrés Giovanni Monroy Charry

Wonsik Yoo

Kang Kevin

David Hunter

The Medical Affairs team at Celltrion Healthcare is responsible for developing and communicating scientific information about the company's biosimilar and biopharmaceutical products. This team collaborates with healthcare professionals, conducts research, and supports clinical education to ensure appropriate usage of therapies like REMSIMA. They play a critical role in bridging the gap between clinical data and real-world application, enhancing patient access to innovative treatments.

Medical Affairs

Sales and Key Account Management

Business Development and Strategy

Medical Affairs

About

Team members

Other teams at Celltrion Healthcare Co.,Ltd.

Sales and Key Account Management

Business Development and Strategy